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pCEL-X softwareIn vitro blood–brain barrier (BBB) models from primary brain endothelial cells can closely resemble the
in vivo BBB, offering valuable models to assay BBB functions and to screen potential central nervous sys-
tem drugs. We have recently developed an in vitro BBB model using primary porcine brain endothelial
cells. The model shows expression of tight junction proteins and high transendothelial electrical resis-
tance, evidence for a restrictive paracellular pathway. Validation studies using small drug-like com-
pounds demonstrated functional uptake and efﬂux transporters, showing the suitability of the model
to assay drug permeability. However, one limitation of in vitro model permeability measurement is the
presence of the aqueous boundary layer (ABL) resulting from inefﬁcient stirring during the permeability
assay. The ABL can be a rate-limiting step in permeation, particularly for lipophilic compounds, causing
underestimation of the permeability. If the ABL effect is ignored, the permeability measured in vitro will
not reﬂect the permeability in vivo. To address the issue, we explored the combination of in vitro perme-
ability measurement using our porcine model with the pKaFLUX method in pCEL-X software to correct for
the ABL effect and allow a detailed analysis of in vitro (transendothelial) permeability data, Papp. Pub-
lished Papp using porcine models generated by our group and other groups are also analyzed. From the
Papp, intrinsic transcellular permeability (P0) is derived by simultaneous reﬁnement using a weighted
nonlinear regression, taking into account permeability through the ABL, paracellular permeability and ﬁl-
ter restrictions on permeation. The in vitro P0 derived for 22 compounds (35 measurements) showed good
correlation with P0 derived from in situ brain perfusion data (r
2 = 0.61). The analysis also gave evidence
for carrier-mediated uptake of naloxone, propranolol and vinblastine. The combination of the in vitro por-
cine model and the software analysis provides a useful tool to better predict BBB permeability in vivo and
gain better mechanistic information about BBB permeation.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).els (Abbott et al., 2014). One important application of in vitro BBB1. Introduction
The blood–brain barrier (BBB) is formed by brain endothelial
cells that line the cerebralmicrovessels and is themajor site for reg-
ulation of molecular trafﬁc between the blood and the central ner-
vous system (Abbott et al., 2010; Abbott, 2014). Methods available
to study the physiology of the BBB include several in vitro BBBmod-models is for use as a permeability assay, to measure the ability of
compounds of interest to cross the BBB and to reveal the underlying
mechanism(s) of permeation. However, to be an effective screening
assay an in vitro BBB model needs to be robust, reproducible, and
with highly restrictive tight junctions tomimic the in vivo condition.
A number of in vitro BBB models have been developed, including
several recently reported (Bernas et al., 2010; Sano et al., 2010;
Hatherell et al., 2011; Lippmann et al., 2013; Xue et al., 2013), but
most of the cell line models and many of the primary cultures show
low transendothelial electrical resistance (TEER), indicating a leaky
cell monolayer. A few models do show high TEER and are in princi-
ple suitable for permeability assays (Franke et al., 1999; Förster
Abbreviations
ABL aqueous boundary layer – adjacent to the
surface of a cell monolayer
BEC, PBEC brain endothelial cell, porcine BEC,
respectively
Daq aqueous diffusivity (cm2 s1)
E(Du) function due to electrical potential drop across
the cell junction (dimensionless)
F(r/R) Renkin molecular sieving function,
dimensionless fraction in the range of 0–1
hABL ABL thickness (cm)
DRW dynamic range window:
DRW = logPABL  logPpara
pKaFLUX apparent pKa derived from the logPapp–pH
proﬁle, the pH at which the resistance to
transport is 50% due to the endothelial cell
monolayer and 50% due to the ABL
PABL in vitro ABL permeability (cm s1)
aPapp in vitro apparent permeability of an
endothelial cell monolayer (cm s1)
PC in vitro transendothelial (cellular)
permeability (cm s1)
PC polycarbonate ﬁlter insert
PE polyester ﬁlter insert
PC
in situ transendothelial permeability (cm s1) from
rodent in situ brain perfusion technique
Pe in vitro permeability of an endothelial cell
monolayer (cm s1), corrected for ﬁlter
permeability
P0, P0in situ intrinsic permeability of uncharged permeant,
in vitro and in situ, respectively (cm s1)
Ppara in vitro paracellular permeability (cm s1)
r hydrodynamic molecular radius (Å)
R membrane junction pore radius (Å)
e/d porosity of paracellular junction pores divided
by the rate-limiting paracellular pathlength
(size-restricted, cation-selective)
(e/d)2 secondary porosity–pathlength ratio
(charge/size nonspeciﬁc ‘‘free diffusion’’ term)
Du electrical potential drop (mV) across the
electric ﬁeld created by negatively-charged
residues lining the junctional pores
a The traditional terminology for permeability across epithelia and endothelia
uses Papp for the experimentally determined ‘apparent permeability’, with Pe the
calculated transendothelial permeability after correction for ﬁlter permeability. By
contrast, Avdeef (2011, 2012) used Pe for apparent permeability. To avoid confusion,
in this paper we revert to the traditional terminology.
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commercially (Culot et al., 2008; Vandenhaute et al., 2012). A key
question is the degree to which permeability data from an in vitro
model reﬂect in vivo BBB permeability, i.e., the quality of in vitro–
in vivo correlation (IVIVC). But often overlooked are the inﬂuence
of the aqueous boundary layer (ABL) and variable/low-TEER on
in vitro permeability measurement.
The ABL, also referred to as the unstirred water layer (UWL), is a
region of poorly-stirred solution adjacent to the cell layer of inter-
est (Korjamo et al., 2008). In vivo, the cerebral capillary network
has an irregular highly branched course and a high velocity of
red blood cells in the circulation (Hudetz, 1997); even in capillaries
with low or no red blood cell trafﬁc, plasma ﬂow has the same stir-
ring effect (Villringer et al., 1994). Therefore, the ABL in vivo is min-
imal. However, in both epithelia and endothelia in vitro, a
signiﬁcant ABL is present adjacent to the cell membrane as a result
of inefﬁcient stirring during the experiment (Barry and Diamond,1984; Youdim et al., 2003; Korjamo et al., 2008) (Fig. 1). Perme-
ation through the ABL is by passive diffusion. Hence, the ABL is a
rate-limiting step for permeation of lipophilic compounds result-
ing in reduction of the apparent permeability (Hidalgo et al.,
1991; Karlsson and Artursson, 1991; Ruell et al., 2003; Avdeef
et al., 2004; Katneni et al., 2008; Velicky´ et al., 2010), leading to
reduced dynamic range and lower resolution in rank-ordering
compound permeation. The ABL can also be a source of bias in
determining the Michaelis–Menten transport kinetic Km because
of the concentration gradient created within the ABL (Wilson and
Dietschy, 1974; Balakrishnan et al., 2007) (Fig. 1). The ABL can also
mask inhibition of speciﬁc carrier-mediated transport based on
similar apparent permeability measured for transporter substrate
in the absence and presence of inhibitors (Naruhashi et al.,
2003). If the ABL effect is ignored, the permeability measured
in vitro will not reﬂect the true permeability in vivo.
Currently there is no quantitative correction for ABL used rou-
tinely for in vitro BBB permeability data. An early study on the effect
of ABL on in vitro BBB permeability by Ng et al. (1993) prompted
awareness of the problem. Since then, most researchers have used
stirring during permeability experiments to minimize the ABL
effect. However, full ABL correction from analysis of in vitro perme-
ability data is rarely used. The most common method to correct for
ABL in in vitro BBB permeability data analysis is subtraction of the
permeability of compounds through blank ﬁlter inserts, Pﬁlter (with-
out cells) from apparent endothelial cell permeability, Papp, to
obtain permeability through the cell monolayers, Pe (e.g., papers
on BBB models using bovine brain endothelial cells (Culot et al.,
2008), porcine brain endothelial cells (Cohen-Kashi Malina et al.,
2009), rat brain endothelial cells (Nakagawa et al., 2009) and the
human brain endothelial cell line hCMEC/D3 (Carl et al., 2010).
The assumption made was that the other resistances to permeation
apart from the cell monolayer are the same in ﬁlter inserts with and
without cells. This method works well for low- and moderately-
permeable test compounds but is subject to considerable uncer-
tainty as the permeability of test compound approaches that of
the aqueous boundary layer permeability limit. This can be partic-
ularly limiting in unstirred solutions. A more systematic and rigor-
ous approach to ABL correction is needed, to reveal the true
permeability across the cell membranes to allow better discrimina-
tion andmechanistic study of transcellular pathways, and to permit
a more accurate correlation analysis against in vivo data.
There are several methods to determine ABL thickness in vitro
(see Korjamo et al., 2009 for a detailed review). One is the pKa shift
method (Gutknecht and Tosteson, 1973) also termed ‘pKaFLUX’
method (Ruell et al., 2003; Nielsen and Avdeef, 2004; Avdeef
et al., 2004, 2005). The pKaFLUX is the pH at the inﬂection point in
the apparent log permeability-pH curve, where the ABL and the
membrane permeability contributions are equal. From the differ-
ence between the true pKa and pKaFLUX, the intrinsic transcellular
permeability of a compound P0 is derived (Avdeef et al., 2005).
The pKaFLUX method has been applied to parallel artiﬁcial mem-
brane permeability assay (PAMPA) and Caco-2 models for predic-
tion of blood-intestinal and blood–brain barrier permeability
(Avdeef et al., 2005; Avdeef, 2011). This method was found to be
more robust than one based on stirring at different RPM for ABL
determination (Korjamo et al., 2008).
We have developed an in vitro porcine brain endothelial cell
(PBEC) model which shows restrictive tight junctions, low paracel-
lular permeability to sucrose and functional expression of polar-
ized uptake and efﬂux transporters (Patabendige et al., 2013a,b).
In the present study, we further investigated the application of
the PBEC model by exploring the combination method of in vitro
PBEC permeability and pKaFLUX analysis to address the ABL and to
predict BBB permeability in vivo. In this pilot study, in vitro perme-
ability assay using the PBEC model for several ionizable
aqueous boundary layer 
aqueous boundary layer capillary blood flow 
endothelial cells 
basement 
membrane 
filter support 
astrocyte endfeet 
BBB in vivo BBB in vitro 
concentration gradient within 
the aqueous boundary layer 
(a) (b) 
Fig. 1. A comparison between blood–brain barrier (BBB) in vivo and in vitro. (a) High velocity capillary blood ﬂow efﬁciently mixes the blood in vivo, hence the aqueous
boundary layer (ABL) is minimal. (b) In vitro, inefﬁcient stirring during the permeability experiment results in the presence of ABL adjacent to the cell membrane;
concentration gradients formed within the ABL can skew transport kinetics. Figure modiﬁed from Youdim et al. (2003).
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in vitro permeability data (Papp), including existing unpublished
and published data (Patabendige et al., 2013a) from the PBEC
model were analyzed for ABL correction and detailed analysis of
permeability data to derive intrinsic transcellular permeability P0.
The in vitro–in vivo correlation of the P0 was assessed.2. Materials and methods
2.1. Materials
Iscove’s Modiﬁed Dulbecco’s Medium (IMDM) 1 and Dul-
becco’s Modiﬁed Eagle’s Medium (DMEM) without Phenol Red
were purchased from Invitrogen Life Technologies Ltd. (Paisley,
UK). Bovine plasma derived serum (BPDS) was from First Link
(UK) Ltd. (Birmingham, UK). RO-20-1724 was purchased from
Merck Chemicals Ltd. (Nottingham, UK). Ko143 and MK571 were
purchased from Tocris Bioscience (Bristol, UK). [3H] propranolol,
[3H] vinblastine, [3H] naloxone and Optiphase HiSafe 2 scintillation
cocktail were purchased from PerkinElmer Life & Analytical Sci-
ences (Buckinghamshire, UK). [14C] acetylsalicylic acid was from
Sigma–Aldrich (Dorset, UK). [14C] sucrose was purchased from
Amersham (UK). [3H] dexamethasone (from PerkinElmer, UK)
was kindly provided by Dr. Sarah Thomas (BBB Group, King’s Col-
lege London). Tariquidar and PSC833 were kindly provided by Dr.
Maria Feldman and GlaxoSmithKline (Hertfordshire, UK) respec-
tively. All other materials were purchased from Sigma–Aldrich
(Dorset, UK). Rat-tail collagen was prepared according to Strom
and Michalopoulos (1982).2.2. Isolation of porcine brain microvessel endothelial cells
The protocol used was as reported in Skinner et al. (2009) and
Patabendige et al. (2013a,b), with slight modiﬁcations. In brief,
brains from six pigs were transported from the abattoir to the
lab on ice in Iscove’s medium with added penicillin (100 U/ml)
and streptomycin (100 lg/ml). The hemispheres were washed,
the cerebellum removed, and meninges peeled off. The white mat-
ter was removed and the gray matter homogenized, then ﬁltered
successively through 150 and 60 lm nylon meshes. The meshes
with retained microvessels were kept separate, and immersed in
medium containing collagenase, DNAse and trypsin to digest the
microvessels. The microvessels were washed off the meshes, resus-
pended and centrifuged. The ﬁnal pellets were resuspended in
freezing medium, aliquoted and stored in liquid nitrogen. Six
brains generated 12 cryovials each of ‘150s’ and ‘60s’ microvessel
fragments, named according to the mesh ﬁlter used (150 and60 lm pore sizes). Cells derived from both 150s and 60s were used
for permeability assays described in the present study.2.3. In vitro BBB model
The cryopreserved microvessel fragments were thawed and cul-
tured according to Patabendige et al. (2013a,b) to obtain primary
porcine brain endothelial cells. Puromycin was used to kill contam-
inating cells such as pericytes. The in vitro BBB model using the pri-
mary porcine brain endothelial cells (PBEC) was set up on rat-tail
collagen/ﬁbronectin (7.5 lg/ml)-coated Corning Transwell ﬁlter
inserts (12 mmmembrane diameter, 1.12 cm2 growth surface area,
0.4 lm pore size), transparent polyester (catalog no. 3460) or
translucent polycarbonate membrane (catalog no. 3401), in
12-well plate. The PBEC were seeded onto Transwell inserts at a
density of 1  105 cells per insert. Conﬂuency was reached within
3–4 days. The culture medium consisting of DMEM with 10% v/v
bovine plasma derived serum, penicillin (100 U/ml), streptomycin
(100 lg/ml), glutamine (2 mM) and heparin (125 lg/ml) was then
changed to serum-free medium with added hydrocortisone
(550 nM) (Hoheisel et al., 1998), and the cells were treated with
8-(4-chlorophenylthio-cAMP) (CPT-cAMP, 250 lM) and a phos-
phodiesterase inhibitor, RO-20-1724 (17.5 lM) for 24 h to increase
the TEER of the cell monolayer (Rubin et al., 1991). The TEER was
measured with STX-100C chopstick electrode pair connected to
EVOM meter (World Precision Instruments Inc., Sarasota, FL,
USA) 1 h before starting the permeability assay, while the cells
were still in culture medium. The Transwellplate was then
returned to the CO2 incubator. To obtain the TEER of the cell mono-
layer, the resistance (X) of a rat-tail collagen-coated blank ﬁlter
insert (without cells) was subtracted from the resistance measured
across the insert with cell monolayer. The resulting value was mul-
tiplied by the surface area of the ﬁlter insert (1.12 cm2) to express
results as X cm2. Quality control of cell monolayer TEER to be used
in permeability assays was set at 200X cm2, above the value rec-
ommended for monolayers to be used for assessing permeability
of drug-like molecules (Gaillard and de Boer, 2000). Data from per-
meability assay of dexamethasone conducted on ‘leaky’ cell mono-
layers with TEER of 140X cm2 were included for comparison.2.4. In vitro permeability assay
DMEM without Phenol Red with added HEPES (25 mM) and
bovine serum albumin (BSA; 0.1% or 4% w/v; see below) was
used as assay buffer. For ionizable compounds: [3H] propranolol
(30 Ci/mmol), [14C] acetylsalicylic acid (11.1 mCi/mmol), [3H]
naloxone (63 Ci/mmol) and [3H] vinblastine (10.9 Ci/mmol),
permeability assays (apical to basal direction) were conducted at
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7.4. BSA was added to the apical compartment (insert) buffer at
0.1% w/v and to the basal compartment (well) buffer at 4% w/v.
The difference in apical-basal pH and BSA percentage were to cre-
ate ionization and lipophilic sinks in the basal compartment
(Avdeef et al., 2005). BSA also helped to maintain tight junction
integrity (Youdim et al., 2003). The permeability assay for the neu-
tral compound [3H] dexamethasone (89 Ci/mmol) was carried out
at apical and basal buffer pH of 7.4, 0.1% w/v BSA in apical and
basal buffer, in the presence of an inhibitor cocktail: tariquidar
(1.16 lM; against P-glycoprotein, P-gp), Ko143 (1 lM; against
breast cancer resistance protein), and MK571 (25 lM). To conﬁrm
the evidence for speciﬁc uptake detected in the data analysis, the
permeability assay for [3H] naloxone was repeated with unlabelled
naloxone added to the apical buffer at 300 lM and 3000 lM to
check for saturability. The permeability assay for [3H] vinblastine
was carried out in the absence and in the presence of P-gp inhibi-
tor, PSC833 (50 lM) added to the apical buffer. [14C] sucrose
(633 mCi/mmol) was used as paracellular marker for [3H] labelled
compounds. Radiolabelled concentrations used were 1.5 lCi/ml for
[3H] labelled and 0.15 lCi/ml for [14C] labelled compounds. The
10 higher [3H] was to compensate for the lower counting
efﬁciency of [3H] vs. [14C] in the liquid scintillation counter and
minimized the effect of spill-over of [14C] counts into the [3H]
counting window.
To start the assay, culture medium in the apical and basal com-
partments was aspirated. Filter inserts were transferred to 12-well
plates containing the pre-warmed basal buffer (1.5 ml) placed on
an orbital shaker. The apical buffer containing radiolabelled com-
pounds (0.5 ml) was added to the ﬁlter inserts. Stirring rates were
set at 200 RPM for propranolol and dexamethasone, 100 RPM for
acetylsalicylic acid and vinblastine (no stirring for naloxone). The
stirring rates were decided based on experimental simulation in
pCEL-X software, to most accurately determine the P0. The assay
was carried out at 37 C for 60 min. At the end of the assay, sam-
ples were taken from the apical and basal compartments and
added to scintillation vials. Optiphase HiSafe 2 scintillation cocktail
was added to the vials. The radioactivity was counted using a Pack-
ard Tri-Carb 2100TR liquid scintillation counter.
Cleared volume (CV, in lL) was calculated to derive permeabil-
ity times surface area product (PS, in lL min1) and thence appar-
ent permeability, PappCV ¼ V  dpmðwellÞ=dpmðinsertÞ ð1Þ
PS ¼ CV=t ð2Þ
Papp ¼ PS=S ð3Þwhere dpm = total disintegration per minute, V = volume in insert
(lL), t = time (min), and S = surface area of the ﬁlter insert (cm2).
Values obtained were divided by 60 to express results in cm s1.
In this pilot study, three ﬁlter inserts (n = 3) were used for perme-
ability assay at each pH.
Mean Papp (cm s1) and the standard deviations (SD) were trans-
formed to logarithmsand imported into the analysis software to cor-
rect for permeability of compound through the ABL, PABL,
contribution from the ﬁlter, Pﬁlter, and the contribution of paracellu-
lar permeability,Ppara to derive the intrinsic transcellular permeabil-
ity, P0, as described in the next section. Published Papp values of [14C]
caffeine, [3H] diazepam, [3H] leucine, [3H] colchicine fromour group
(Patabendige et al., 2013a), and Papp values of [14C] lamotrigine, [14C]
phenytoin and [3H] digoxin from a collaborative project (Dickens
et al., 2013) were also analyzed to derive P0. The P0 values obtained
were included in the in vitro–in vivo correlation (Section 2.6).2.5. The ‘‘intrinsic’’ standard state for in vitro–in vivo correlation
When rigorously comparing physicochemical properties of ion-
izable compounds, it is a useful practice to normalize the measured
properties to a standard state in which the molecule is uncharged.
Many useful physical property descriptors (Abraham descriptors,
hydrogen-bonding potentials, etc.) are only valid in reference to
such a standard state. One could have deﬁned a different standard
state, e.g., pH 7.4. However, fundamental properties of molecules
would be difﬁcult to compare if the molecules had substantially
different pKa values. In the traditional (uncharged-molecule) stan-
dard state used here, the pKa effect is factored out, along with other
effects, such as those associated with transport by aqueous diffu-
sion through the paracellular channels and the aqueous boundary
layer. Thus, ‘‘intrinsic’’ permeability refers to the passive lipoidal or
carrier-mediated permeability of the test compound in its
uncharged form. The mathematical treatment of such ‘‘normaliza-
tion’’ and use of the pCEL-X software is described in detail in
Appendix A.
The objective of our study was to convert the measured appar-
ent permeability, Papp, from two different model systems to a com-
mon (intrinsic) standard state. The hydrodynamic environments of
the two permeability assays (in vitro cell monolayer and in situ
brain perfusion) are very different. In the meta-analysis of several
in vitro endothelial cell models of blood–brain barrier permeability
(benchmarked by in situ brain perfusion measurements), Avdeef
(2011) found that logPapp poorly correlated to logPCin situ. The r2 fac-
tors for the porcine, bovine, rodent, and human in vitro models
were 0.33, 0.09, 0.04, and 0.14, respectively. However, when the
log of the intrinsic permeability coefﬁcients were compared, the
corresponding r2 values rose to 0.57–0.58.
2.6. In vitro–in vivo correlation (IVIVC)
Published Papp measured in other in vitro porcine BBB monocul-
ture models (Franke et al., 1999, 2000; Lohmann et al., 2002; Zhang
et al., 2006) and rodent in situ brain perfusion data (Dagenais et al.,
2009; Avdeef, 2012) were collected from the literature and ana-
lyzed in pCEL-X to correct for ABL and ionization (for in vitro and
in vivo data), paracellular permeability and ﬁlter restriction (for
in vitro data only) to derive the intrinsic transcellular permeability
P0. The in vitro P0 were plotted against the P0in situ to obtain the
in vitro–in vivo correlation (IVIVC; Avdeef, 2011). In the present
study, the P0 values of the compounds analyzed were incorporated
into the previous IVIVC data. The linear regression coefﬁcient was
obtained for the pooled in vitro and in vivo (in situ) data.3. Results
Table 1 lists the molecules analyzed in the study along with
their measured and predicted physicochemical properties. Table 2
summarizes the in vitro PBEC measured data, together with the
characteristics of the permeability experiments. Table 3 lists the
permeability model reﬁnement results. Table 4 summarizes the
averaged logP0in situ values compiled from published rodent
in situ brain perfusion studies from multiple sources (Avdeef,
2012). These logP0in situ values were compared to logP0 based on
PBEC measurements in the IVIVC.
3.1. Effect of ﬁlter porosity on permeability of propranolol
To determine the intrinsic transcellular permeability (P0) of pro-
pranolol, the permeability assay was ﬁrst carried out at multiple
pH using cell monolayers grown on Corning Transwell polyester
membrane (Transwell-Clear) ﬁlter inserts. The polyester
Table 1
Physicochemical properties of studied compounds.
Compound pKa137 C pKa237 C logPOCT Daqb (106 cm2 s1)
Acetylsalicylic acid 3.47a 0.90 9.42
Caffeine – 0.07 9.11
Colchicine – 1.10c 6.57
Dexamethasone – 1.74 6.62
Diazepam 3.24a 2.80 7.66
Digoxin – 1.26c 4.85
Lamotrigine 5.13a 1.68c 8.04
L-Leucine 2.39
a 9.34a 1.55 10.9
Naloxone 7.82a 9.26a 2.18 7.19
Phenytoin 8.08a 2.24 8.09
Propranolol 9.16 3.48 7.99
Vinblastine 5.82 7.57 4.16c 4.77
a Calculated from 25 C value, using pCEL-X. All measured values of ionization
constants, octanol–water partition coefﬁcients are taken from compilations in
Avdeef (2012).
b Calculated by pCEL-X.
c Calculated by ACDLabs Percepta computer program (www.ACDlabs.com).
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scope. pH-dependent permeability was expected for propranolol.
However, the experimental logPapp vs. pH appeared as a ﬂat line
(Fig. 2a), therefore, P0 could not be determined (dashed curve in
Fig. 2a is calculated from the P0 in Fig. 2b). The assay was repeatedTable 2
Data used in the analysis.
Compound pH Mass balance (%) Papp (in 106 cm/s
Acetylsalicylic acid 5.5 101 7.364
6.5 100 4.341
7.4 99 4.109
8.5 97 5.838
Caffeine 8.6 – 15.52a
Colchicine (without inhibitor) 8.6 – 7.56a
Colchicine (P-gp inhib. cocktail) 8.6 – 12.36a
Dexamethasone 7.4 105 25.474
Diazepam 8.6 – 12.67a
Digoxin (without inhibitor) 7.4 102 5.828b
Digoxin (+100 lM verapamil) 7.4 94 9.280b
Lamotrigine 7.4 102 20.289b
L-Leucine 8.6 – 12.42
a
Naloxone (0.02 lM tracer) 5.5 103 6.709
6.5 100 6.557
7.4 94 6.008
8.5 90 6.937
Naloxone (300 lM cold) 5.5 96 5.439
6.5 98 5.873
Naloxone (3000 lM cold) 5.5 98 5.474
6.5 95 6.287
Phenytoin 7.4 98 21.508b
Propranolol 5.5 90 30.400
6.5 88 29.019
7.4 85 27.386
8.6 83 24.166
Propranolol 5.5 100 20.203
6.0 97 30.464
6.5 106 44.305
7.4 98 48.972
Vinblastine (without inhibitor) 5.5 102 1.603
6.5 107 1.966
7.4 103 2.143
8.6 108 5.542
Vinblastine (+50 lM PSC833) 5.5 101 2.813
6.5 108 4.267
7.4 96 3.736
For TEER, data are mean ± SD.
a From Patabendige et al. (2013a).
b From Dickens et al. (2013).with cell monolayers grown on Corning Transwell polycarbonate
membrane inserts. The logPapp at pH 7.4 was higher than the value
obtained from assay using cells grown on Transwell-Clear, and
pH-dependent permeability was then observed (Fig. 2b). pKaFLUX
was detected at pH 5.9. The approximate logP0 was derived
according to Eq. (A.12) and subsequently reﬁned (Appendix A).
The results suggest that the polyester membrane with lower pore
density (4  106 pores/cm2) than polycarbonate membrane
(1  108 pores/cm2) restricted permeability of the highly perme-
able propranolol.3.2. Derivation of intrinsic transcellular permeability, P0, from
apparent permeability, Papp
The measured Papp data (black circles) for compounds of differ-
ent chemistry: acetylsalicylic acid and phenytoin (acids), diazepam
and lamotrigine (bases), leucine (zwitterion), caffeine, and dexa-
methasone (neutral drugs) were analyzed to derive P0, corrected
for permeability through the aqueous boundary layer (PABL) and
paracellular permeability (Ppara) (Fig. 3). The PABL was determined
using propranolol as marker based on the initial ﬁnding that pro-
pranolol permeability was limited by the ABL (Fig. 2b).
From Fig. 3a, it is possible to deduce that the permeability of
acetylsalicylic acid is limited by the ABL at pH < 4, based on theunits) logPapp logSD Insert RPM TEER (X cm2) e/d2
5.141 0.103 PC 100 345 ± 55 0.47
5.366 0.068
5.398 0.122
5.234 0.016
4.809 0.007 PE 200 212 ± 46 0.92
5.122 0.063 PE 200 347 ± 85 0.49
4.908 0.194 349 ± 131 0.49
4.594 0.043 PC 200 140 ± 30 1.57
4.897 0.093 PE 200 264 ± 48 0.67
5.234 0.045 PE 100 388 ± 12 0.43
5.032 0.023 504 ± 64 0.31
4.693 0.015 PE 100 402 ± 14 0.41
4.906 0.024 PE 200 223 ± 52 0.85
5.174 0.026 PC 0 438 ± 32 0.23
5.189 0.085
5.223 0.045
5.162 0.061
5.266 0.051 PC 0 497 ± 27 0.23
5.234 0.064
5.262 0.032 PC 0 497 ± 17 0.31
5.202 0.006
4.667 0.043 PE 100 386 ± 16 0.44
4.517 0.012 PE 200 526 ± 50 0.30
4.538 0.016
4.563 0.008
4.617 0.009
4.695 0.015 PC 200 375 ± 64 0.64
4.516 0.019
4.354 0.007
4.310 0.019
5.795 0.020 PC 100 1007 ± 48 0.29
5.706 0.110
5.669 0.090
5.256 0.016
5.553 0.050 PC 100 978 ± 42 0.29
5.376 0.090
5.448 0.167
Table 3
Results of data analysis.
Compound logP0 logPpara logPABL logPﬁlter logPuptake logPefﬂux GOF
Acetylsalicylic acid 3.31
±0.01
5.35
±0.01
4.40 2.90 – – 0.8
Caffeine 4.65 5.08 4.25 4.14 – – –
Colchicine (without inhibitor) 5.14
±0.04
5.49 4.25 4.28 – – –
Colchicine (P-gp inhib. cocktail) 4.71
±0.06
5.49 4.25 4.28 – – –
Combined 4.85
±0.07
– 5.18
±0.06a
6.5b
0.4
Dexamethasone 4.45 4.85f 4.25 3.05 – – –
Diazepam 4.76 5.29 4.25 4.21 – – 1.8
Digoxin (without inhibitor) 5.20 5.68 4.40 4.42 – – –
Digoxin (+100 lM verapamil) 4.79 5.82 4.40 4.42 – – –
Combined 4.78
±0.01
– 5.00
±0.01a
6.2b
0.0
Lamotrigine 3.94 5.48 4.40 4.19 – – –
L-Leucine 4.91 5.03 4.25 4.07 – – –
Naloxone (0.02 lM tracer) 3.34 5.78f 5.13 3.01 4.23
±0.27
– 1.0
Naloxone (300 lM cold) 3.76 5.79f 5.13 3.01 4.75 – –
Naloxone (3000 lM cold) 3.31 5.65f 5.13 3.01 4.78 – –
Combined 3.34
±0.12
5.75 5.13 3.01 4.29
±0.26c
1.1
4.78
±0.09d
4.77
±0.05e
Phenytoin 3.67 5.45 4.40 4.19 – – –
Propranolol 0.96
±0.08
5.29f 4.25
±0.02
2.97 5.48
±0.54
– 1.4
Vinblastine (without inhibitor) 5.28
±0.03
5.86f 4.40 3.19 6.56
±0.16
– 1.3
Vinblastine (+50 lM PSC833) 5.14
±0.55
5.86f 4.40 3.19 5.73
±0.11
– 1.1
Combined 5.28
±0.04
5.73 <8b
5.80
±0.04a
1.1
a Without inhibitor.
b With inhibitor.
c Tracer concentration.
d 300 lM non-radiolabeled naloxone.
e 3000 lM non-radiolabeled naloxone.
f Ppara from sucrose Papp.
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reﬁned logP0 of 3.31 ± 0.01. Also, for acetylsalicylic acid, it was
possible to reﬁne the Ppara constant (5.35 ± 0.01) using the mea-
sured logPapp vs. pH data. The reﬁned Ppara constant predicts a TEER
value of 286X cm2 (Eq. (A.8), Appendix A), which is within the
experimental error of the measured TEER of 345 ± 55X cm2
(Table 2), suggesting that logPapp for pH > 6 (Fig. 3a) is consistent
with paracellular permeability, and not predictive of an uptake
process of the acetylsalicylate anion. The measurement at pH 8.5
was reproducibly higher than the model would predict, suggesting
a possible increased paracellular leakage at pH 8.5. The data point
was ultimately assigned a zero weight in the reﬁnement. A similar
effect appears to have taken place with verapamil at pH 4.8
(Avdeef et al., 2005).
For all of the other molecules in Fig. 3, Ppara was estimated using
Eq. (A.8), where TEER measurements were used to calculate Papp of
sucrose, from which (e/d)2 was calculated (Eq. (A.11)) and applied
to each of the drugs in Fig. 3b–g to estimate the corresponding
value of Ppara during the reﬁnement step (Appendix A.5). These
logPpara values ranged from 5.03 (L-leucine) to 5.82 (digoxin).
The permeability of caffeine (Fig. 3b), diazepam (Fig. 3d) and
leucine (Fig. 3f) were not limited by the ABL. To derive the intrinsictranscellular permeability (P0) of the compounds, the logPapp vs.
pH calculated (the sigmoidal solid curves or solid lines) was ﬁtted
to the logPapp measured and simultaneously reﬁned by weighted
nonlinear regression with PABL, Ppara and Pﬁlter kept as ﬁxed contrib-
utors. For dexamethasone, the cell monolayer used for the perme-
ability assay was of low resistance (TEER  140X cm2) and high
logPpara (4.85) (Fig. 3c).
3.3. Uptake and efﬂux permeability; deviation from predicted passive
transcellular permeability
Fig. 4 illustrates carrier-mediated effects in the case of naloxone
(Fig. 4a), vinblastine (Fig. 4b), colchicine (Fig. 4c), and digoxin
(Fig. 4d). For naloxone and vinblastine, Ppara was estimated from
the simultaneously determined sucrose Papp, while for colchicine
and digoxin, Ppara was estimated using the relationships in Eqs.
(A.8) and (A.11) in Appendix A (cf., Table 3). Since naloxone was
measured without stirring, the propranolol ABL marker could not
be used. Since PC ﬁlter inserts were used in the cases of naloxone
and vinblastine, Pﬁlter did not contribute to the determined logP0 in
any signiﬁcant way. However, PE ﬁlter inserts were used in the
cases of colchicine and digoxin, which increased the contribution
Table 4
Intrinsic permeability values derived from rodent in situ brain perfusiona.
Compound logP0 (wild type) logP0 (‘passive’)b
Acetylsalicylic acid 3.38d
Caffeine 3.81 ± 0.17
Colchicine 5.61 ± 0.20 5.11 ± 0.23
Cyclosporine A 4.42 ± 0.64
Dexamethasone 4.65 ± 0.03e
Diazepam 3.40 ± 0.34 3.26 ± 0.09
Digoxin 6.31 ± 0.17
Dopamine 2.68
Gabapentin 4.59 4.45 ± 0.15
Haloperidol 2.46
Lamotrigine 4.67
L-Leucine 3.97 ± 0.49 6.07
Metoprolol 3.70 ± 0.36e
Morphine 4.78 ± 0.48 4.78 ± 0.10
Naloxone 3.13c 3.97c
Neramexane 2.17d
L-Phenylalanine 3.66 ± 0.45 5.41 ± 0.46
Phenytoin 4.20 ± 0.05 4.09 ± 0.10
Propranolol 1.26 ± 0.21
Quinidine 3.99 ± 0.39 3.08 ± 0.35
Testosterone 3.42 ± 0.45
Theophylline 5.05 ± 0.25
Vinblastine 5.17 ± 0.15 4.95 ± 0.11
a Averaged values taken from Table 9.7 in Avdeef (2012).
b Averaged logP0 of Kd values, or those at saturation concentrations, or those
measurements with inhibitors: PSC833, GF120918, or Pgp-knock out (mdr1a(/))
mouse models.
c Extracted from data in Suzuki et al. (2010).
d Calculated by pCEL-X.
e Taken as the Caco-2 value (Avdeef, 2012).
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effect on the reﬁnement of logP0 values (cf., Fig. 4c and d).3.3.1. Naloxone
The big difference between the logPapp–pH (solid curve) and
logPC–pH (dashed curve) curves at low pH in Fig. 4a for naloxone
showed evidence for uptake via transporters. The permeability
assay was repeated to include unlabelled naloxone (300 and
3000 lM) to conﬁrm transporter saturation.Fig. 2. Effect of ﬁlter porosity on permeability of propranolol. Log permeability-pH proﬁl
polyester and (b) polycarbonate membrane ﬁlter inserts (Corning Transwell, 12 mm m
apical to basal permeability assays were conducted at multiple pH in apical buffer and p
200 RPM. The black circles are logPapp measured. The hyperbolic dashed curves represent
through the aqueous boundary layer (ABL). The ﬁlter limit (dashed-dotted lines) was fr
Paracellular permeability, Ppara (dashed-double-dotted lines) was determined from [14C] s
the measured logPapp and simultaneously reﬁned with the ﬁxed contributors: PABL, P
permeability, P0. In (b), data analysis showed possible uptake transport at low pH (<5).The tracer (0.02 lM) naloxone set could not be reﬁned for logP0
since the ABL was nearly entirely limiting the permeation. Conse-
quently, the twopartly-saturated sets (300 and3000 lMcoldnalox-
oneadded to the tracer level)were combined in reﬁnement toobtain
logP0 = 3.28 ± 0.02, logPABL = 5.13 ± 0.03, and logPuptake = -
4.81 ± 0.06. These values were then used in the tracer set to reﬁne
just logPuptake, which produced4.23 ± 0.26, a value thatwas nearly
masked by the swamping ABL effect. The three sets were then com-
bined in a overall calculation to produce the ﬁnal set of reﬁned con-
stants logP0 = 3.34 ± 0.12, logPABL = 5.13 (ﬁxed), and three values
of logPuptake (4.29 ± 0.26, 4.78 ± 0.09, 4.77 ± 0.05), correspond-
ing to the 0.02, 300, and 3000 lM sets, respectively. This analysis
clearly indicated that the positively charged form of naloxone
crosses the cell membranes via a saturable uptake mechanisms,
apparently involving a high capacity transporter, since 3000 lM
cold naloxone was not enough to saturate the transporter entirely.3.3.2. Vinblastine
The efﬂux substrate vinblastine showed higher P0 when P-gp
efﬂux transporter was inhibited by 50 lM PSC833 (Fig. 4b, check-
ered circles). The curves were shifted both in the region of the cat-
ion and the neutral species, suggesting that vinblastine in both
forms may be subject to efﬂux. Hence, it appeared that vinblastine
was simultaneously subject to uptake and efﬂux carrier-mediated
processes.
Sucrose Papp was used to estimate Ppara in the vinblastine assay.
Since the wells were stirred at 100 RPM, the propranolol-based
logPABL at 200 RPM was lowered by 0.15 according to Eq. (A.6).
The logPpara, logPﬁlter, and logPABL were added as ﬁxed contribu-
tions, as logP0 and logPuptake were reﬁned (Appendix A.5) for the
non-inhibitor and added-inhibitor (50 lM PSC833) sets. Both the
intrinsic and the uptake permeability values appeared to be
affected by efﬂux (Table 3). The two sets were then combined, with
the repeated reﬁnement yielding logP0 = 5.28 ± 0.04,
logPuptake = 5.73 (kept ﬁxed), and logPefﬂux = 5.80 ± 0.04 for the
non-inhibitor set and logPefﬂux < 8 for the +50 lM PSC833 set.
This suggested that efﬂux was essentially suppressed by the inhib-
itor. With the logPefﬂux of 5.80, it was possible to rationalize the
extent to which the individual-set reﬁned logPuptake and logP0 in
the two sets were different.es of [3H] propranolol across porcine brain endothelial cell monolayers grown on (a)
embrane diameter, 1.12 cm2 surface area, 0.4 lm pore size, in 12-well plates). The
H 7.4 in the basal buffer for 60 min at 37 C while stirring on the orbital shaker at
the transendothelial permeability of propranolol. PABL (dotted lines) is permeability
om experimentally determined percentage porosity of blank ﬁlters (without cells).
ucrose permeability. The sigmoidal solid curves (log permeability-pH) were ﬁtted to
ﬁlter and Ppara by a weighted nonlinear regression to derive intrinsic transcellular
Each data point represents n = 3 ﬁlter inserts.
Fig. 3. Derivation of the intrinsic transcellular permeability, P0 from apparent permeability, Papp. Papp measured were analyzed to derive P0 corrected for aqueous boundary
layer (ABL) effect and paracellular permeability. For (a) [14C] acetylsalicylic acid, the permeability assay was conducted at multiple pH in the apical buffer and pH 7.4 in the
basal buffer for 60 min at 37 C while stirring at 100 RPM. For (c) [3H] dexamethasone, the assay was conducted at apical and basal buffer pH of 7.4 for 60 min at 37 C and
200 RPM, in the presence of inhibitor cocktail: tariquidar (1.16 lM), Ko143 (1 lM) and MK571 (25 lM). Papp data for (b) [14C] caffeine, (d) [3H] diazepam and (f) [3H] L-leucine
were from Patabendige et al. (2013a), where the stirring ratewas 200 RPM and Transwell-Clear inserts (polyestermembrane) were used. Papp data for (e) [14C] lamotrigine and
(g) [14C] phenytoin were from a collaborative project (Dickens et al., 2013), where the stirring rate was 100 RPM and Transwell-Clear inserts were used. The black circles
are logPapp measured. Permeability through the ABL, PABL was determined using propranolol as marker. The ﬁlter limits were from porosity of blank polyester and
polycarbonate ﬁlter membranes without cells. Paracellular permeability, Ppara, was estimated from the measured TEER, except for (c) dexamethasone, the Ppara of which was
from [14C] sucrose permeability. Transcellular permeability, PC (indicated by hyperbolic dashed curves or dashed lines) depends on pH for ionizable compounds i.e. (a)
acetylsalicylic acid (acid), (d) diazepam (base), (e) lamotrigine (base), (f) L-leucine (zwitterion) and (g) phenytoin (acid). Permeability of neutral compounds does not depend on
pH i.e. (b) caffeine and (c) dexamethasone. The sigmoidal solid curves or solid lines (log permeability-pH)were ﬁtted to the logPappmeasured (black circles) and simultaneously
reﬁned by weighted nonlinear regression with PABL, Ppara and Pﬁlter to derive intrinsic transcellular permeability P0. Each data point represents n = at least 3 ﬁlter inserts.
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Fig. 4c and d shows colchicine and digoxin with added efﬂux
inhibitor (checkered circle) and no-inhibitor (black circles). The
addition of inhibitors increases the apparent permeability by
nearly the same amount in both drugs, consistent with the sup-
pression of efﬂux transporter.
3.4. In vitro–in vivo correlation analysis
To assess the ability to predict in vivo BBB permeability of a com-
pound from permeability data measured using the PBEC model, P0
(in vitro) derived from our PBEC model permeability data was plot-
ted against P0in situ (in vivo) derived from in situ brain perfusion data
in rodents (Fig. 5). Published data from other in vitro porcine BBB
models were also included in the linear regression analysis. The r2
value of 0.61 shows a good correlation for the pooled data.4. Discussion
4.1. Principal ﬁndings of this study
The in vitro blood–brain barrier (BBB) model from primary por-
cine brain endothelial cells (PBEC) which shows a restrictive para-
cellular pathway was used for permeability studies of small drug-
like compounds of different chemistry: acid, bases, neutrals and
zwitterions. Assay at multiple pH was conducted for the ionizable
compounds propranolol, acetylsalicylic acid, naloxone and vinblas-
tine to plot permeability vs. pH. The pCEL-X software (Section 2.5
and Appendix A) was used for detailed permeability data analysis,
including aqueous boundary layer (ABL) correction. The ABL was
found to restrict propranolol permeability, which was also limited
by low pore density of the Transwell-Clear polyester ﬁlter mem-
brane. The intrinsic transcellular permeability P0 showed good
Fig. 4. Uptake and efﬂux permeability. Apical to basal permeability assays for (a) [3H] naloxone and (b) [3H] vinblastine were conducted for 60 min at 37 C, unstirred for
naloxone and stirring at 100 RPM for vinblastine. Unlabelled naloxone was added to the apical buffer at 300 lM (ﬁlled squares) and 3000 lM (ﬁlled circles) to check for
uptake saturability. Unﬁlled squares correspond to labelled (0.02 lM) naloxone. The permeability assay for vinblastine was carried out in the absence and in the presence of
P-glycoprotein inhibitor, PSC833 (50 lM) in the apical compartment. Papp data for (c) [3H] colchicine and (d) [3H] digoxin are from Patabendige et al. (2013a) and Dickens et al.
(2013) respectively. The inhibitors used in the colchicine assay were PSC833 (50 lM), GF120918 (25 lM) and MK571 (25 lM), added to the apical compartment. The squares
and the circles are the measured logPapp. The hyperbolic dashed curves (a and b) and dashed lines (c and d) indicate transcellular permeability. For vinblastine, colchicine and
digoxin, permeability through the aqueous boundary layer, PABL (indicated by the dotted lines) was determined using propranolol as marker. Paracellular permeability, Ppara
(indicated by the dashed-double-dotted lines) was from [14C] sucrose permeability (a and b) or estimated from TEER measured (c and d). The permeability through ﬁlter, Pﬁlter
(indicated by the dashed-dotted lines) was determined from ﬁlter porosity. The sigmoidal solid curves or solid lines (log permeability-pH) were ﬁtted to the measured logPapp
and simultaneously reﬁned by weighted nonlinear regression with PABL, Ppara and Pﬁlter as ﬁxed contributors to derive the intrinsic transcellular permeability P0. LogPuptake and
logPefﬂux decrease (more negative values) with addition of unlabelled naloxone (a) and inhibitors (b-d). LogP0 + efﬂux increases (less negative values) in presence of inhibitors
(b-d). LogP0 show overall reﬁnement of the combination analysis of all sets (without and with unlabelled compound or inhibitors). Each data point represents at least n = 3
ﬁlter inserts.
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in vitromodel.
4.2. pCEL-X software for correction of ABL, designing experiments and
detailed analysis of permeability data
Stirring helps to diminish the ABL thickness, but it cannot
reduce it entirely. This is because the aqueous medium adjacent
to the membrane surface is less mobile due to hydrogen bonds
formed at the interface (Loftsson and Brewster, 2008). Hence, even
vigorous stirring is unable to remove the ABL totally. Furthermore,
excessive stirring is undesirable, since it can compromize tight
junction integrity (cf., Zhang et al., 2006: 600 RPM). Application
of the pKaFLUX method for ABL correction using pCEL-X proved use-
ful particularly for ionizable compounds. The method is still appli-
cable for non-ionizable compounds provided that a marker for ABL,
preferably an ionizable lipophilic compound, is included.
Two main boundaries in the log permeability-pH plot are ABL
and paracellular permeation (Fig. 6). The boundaries create a
‘dynamic range window’ (DRW), as evident in the plots (Avdeef,
2011). The sigmoidal log permeability-pH curve reaches a plateau
at the ABL limit at the top, and at the paracellular limit at the
bottom of the DRW (cf., Fig. 6). If experimental data are withinthe DRW, intrinsic transcellular permeability with ABL correction
can be derived. However, there are two pitfalls, if just a single-
pH measurement is performed. Firstly, if the data are on the ABL
limit, then permeability measured in the experiment simply
reﬂects diffusion through the ABL. Secondly, if the monolayer used
for the permeability assay was leaky to start with or a leak
developed with vigorous stirring during the assay, the data could
be on the paracellular permeation limit and merely reporting
paracellular permeation of the compound.
A good example of how multiple-pH measurements overcome
the ﬁrst problem is permeability assay of the lipophilic base pro-
pranolol at physiological pH 7.4. From the results in this study, at
pH 7.4 the measured logPapp for propranolol is on the ABL limit.
However, because the assay was conducted at multiple pH, guided
by prediction from pCEL-X, some of the data points are within the
DRW. Therefore, the ABL-corrected intrinsic transcellular perme-
ability could be derived. Care should be taken when choosing a sin-
gle pH for permeability assay of lipophilic bases. For the second
problem, cell monolayers with TEER value of 140 O cm2 were
found to be very leaky in the permeability assay of dexamethasone.
However, dexamethasone is relatively lipophilic, and hence the
leakiness has a minimal interference on the determined logP0
(cf., Fig. 3c). In an in vitro co-culture BBB model of primary bovine
Fig. 5. In vitro–in vivo correlation analysis (IVIVC). Intrinsic transcellular perme-
ability (P0) data from the present study including published data generated from
other porcine models were compared with in situ brain perfusion data from rodent.
Papp data were corrected for aqueous boundary layer (ABL) permeability, paracel-
lular permeability, ﬁlter restriction and possible uptake of the charged species. In
situ brain perfusion data from rodent were collected from the literature and
analyzed using the pKaFLUX method to derive P0 (Dagenais et al., 2009; Suzuki et al.,
2010; Avdeef, 2011, 2012). The predictions for in situ BBB permeation of
acetylsalicylic acid and neramexane (calculated from pCEL-X), and dexamethasone
and metoprolol (Caco-2 values) were used in the analysis (underlined). The solid
line is the linear regression with r2 value of 0.61. The dashed line is the reference
‘line of identity’.
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ation increased exponentially when TEER was below 131 O cm2
and 122 O cm2 when sodium ﬂuorescein (376 Da) and FITC-
labelled dextran (4 kDa) respectively were used as paracellular
markers (Gaillard and de Boer, 2000). For ionizable compounds, if
sufﬁcient data points at different pH fall within the DRW, then
the intrinsic transcellular permeability P0 can still be derived.
Hence, one way to make use of leaky cell monolayers is to conductFig. 6. pKaFLUX method to derive intrinsic transcellular permeability, P0, illustrated
with an ionizable base (pKa  9). The sigmoidal solid curve represents the apparent
permeability, logPapp. The inﬂection point in the curve shows the apparent pKa or
pKaFLUX. The hyperbolic dashed curve represents the transendothelial (cellular)
permeability of the compound, logPC (cell), with the curve maximum indicating
intrinsic transcellular permeability, logP0. The horizontal dotted line shows the
aqueous boundary layer permeability of the compound, logPABL. The horizontal
dashed-double-dotted line represents the paracellular permeability, logPpara. The
gap between the aqueous boundary layer and the paracellular permeability
boundaries, DRW (dynamic range window), is a zone where the apparent
permeability contains an appreciable transendothelial (cellular) contribution. The
dashed-dotted line shows permeability through ﬁlter insert, logPﬁlter. Uptake and
efﬂux transports are indicated by logPuptake or logPefﬂux horizontal lines respectively.the permeability assay at multiple pH provided that the com-
pounds of interest are ionizable (e.g., acetylsalicylic acid, Fig. 3a).
The deﬁned DRW boundaries indicate that the permeability of
the neutral form of a lipophilic compound may be limited by the
ABL, while the permeability of the charged form (i.e., cation or
anion) may be limited by the paracellular pathway. For moderately
lipophilic compounds (P0 < PABL), the top horizontal section of the
sigmoidal curve is not limited by the ABL (e.g., diazepam,
Fig. 3d), but the bottom horizontal portion may still be limited
by the paracellular pathway. If a paracellular marker was used in
the assay to deﬁne the paracellular limit, deviation of the experi-
mental data from this limitation could suggest presence of uptake
mechanism(s) for the charged form of a compound. With pCEL-X
analysis, naloxone and vinblastine showed such pH-dependent
deviation in the present study. At physiological pH 7.4, both com-
pounds are charged (cationic). Organic cation transport system
could be involved in uptake of these compounds. Although it was
not possible to detect uptake transport in the case of acetylsalicylic
acid (nor was such a process reported in the literature for the mol-
ecule), a similar molecule, salicylic acid, the primary metabolite of
acetylsalicylic acid, was found at high concentration in the brain
(brain-to-blood concentration ratio 1.06) after intraperitoneal
injection of acetylsalicylic acid in mice (Prins et al., 2009). Our ﬁnd-
ing of concentration-dependent permeation of naloxone is consis-
tent with in vivo studies by Suzuki et al. (2010) reporting
concentration-dependent uptake of naloxone in rat brains as mea-
sured by the Brain Uptake Index (BUI). The uptake mechanism is
proposed to involve a pH-dependent cationic H1-antagonist trans-
porter (Suzuki et al., 2010). The results provide evidence that the
combination of our in vitro BBB model from PBEC with detailed pKa-
FLUX analysis reaches the same conclusion as in vivo studies, further
validating the PBEC model and conﬁrming its ability to predict
in vivo BBB function.
4.3. Limitations of the method used to derive intrinsic transcellular
permeability P0
The intrinsic transcellular permeability P0 derived from mea-
sured Papp can reﬂect a purely transcellular passive permeation
or a combination of passive and carrier-mediated mechanism(s).
While uptake of charged forms can be clearly revealed, speciﬁc
transport of the neutral form is not as easily recognized unless
the assay is repeated to include transport inhibitors or unlabelled
compounds to provide competition for uptake. A decrease in P0
in the presence of competing substrates suggests uptake mecha-
nism(s) and an increase in P0 in the presence of inhibitors suggests
that the compoundmay be subject to efﬂux mechanism(s). For ion-
izable compounds, if the assay is conducted at a single pH, uncer-
tainty may arise in the analysis. The uncertainty derives from
difﬁculty in determining the pKaFLUX or ‘bend in the curve’ when ﬁt-
ting all the parameters to the experimental data. One way to
reduce the uncertainty is by deﬁning at least one boundary, i.e.,
ABL or paracellular permeation, using appropriate markers. The
method would be moderately demanding for screening purposes,
but its value would be predictive information from pCEL-X before
permeability experiments, helping to design experiments better,
thus saving time and resources. Also, detailed data analysis in
pCEL-X after experiments gives additional information and insights
into permeability mechanisms.
4.4. Other approaches to correct in vitro permeability data for ABL and
ﬁlter resistance to derive intrinsic permeability
A similar approach to correct for ABL and reﬁne measured per-
meability data to derive intrinsic permeability across Caco-2 cells
was proposed by Yu and Sinko (1997). Phenylalanine was used
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chamber were used to study the ABL. The ﬁlter restriction of Snap-
well polycarbonate and Snapwell-Clear polyester membranes was
compared. Permeability through blank ﬁlter inserts was measured
to obtain Pblank for all compounds. The authors proposed that Pblank
is a combination of permeability through ABL and ﬁlter inserts (cf.,
Eq. (A.1)).
The PABL and Pﬁlter were uncoupled with regression analysis of
Pblank as a function of stirring rate to derive Pﬁlter. Consistent with
our ﬁndings, the polyester membrane of Snapwell-Clear was found
to restrict permeability of the highly permeable lipophilic molecule
progesterone.
Grouping of PABL, Pﬁlter and permeability through other resis-
tances in the transport study system, designated PSYS was also
practised by Carl et al. (2010). The PSYS was represented and mea-
sured as Pblank. To derive the permeability across the hCMEC/D3
cell monolayer, PSYS was subtracted from the Papp data.
Subtraction of Pblank from Papp to derive Pmonolayer is appropriate
if the two parameters PABL and Pﬁlter are the same in blank ﬁlter
inserts and in the presence of the cell monolayer. However, the
ABL can be thinner in blank inserts (Hidalgo et al., 1991). The cel-
lular permeability coefﬁcient, PC, was introduced through studies
at different stirring rates by Karlsson and Artursson (1991). ABL
also depends on the interaction between the aqueous phase and
membrane surface (Loftsson and Brewster, 2008) including a com-
plex glycocalyx that differs between cell models. Hence, the inter-
action between the aqueous buffer and the cell membrane surface
will be different from the interaction between the buffer and either
coated or uncoated porous membrane surface. The Pﬁlter in the
presence of cells will tend to be lower because tight adherence of
the cells will increase the path length to accessible pores, and some
pores may be occluded or restricted by ﬁne processes extending
from the basolateral membrane surface. These differences could
bias calculation of the cell monolayer permeability. Pﬁlter will not
inﬂuence the intrinsic transcellular permeability (P0) calculation
if it is not a rate-limiting step. Experimental permeability data
are reﬁned to correct for ABL and eliminate the effect of paracellu-
lar permeation to derive the P0. A possible complication arises if
the PABL of the compound tested is not the same as PABL of the mar-
ker used and if Ppara of the compound is not equal to the measured
permeability of the paracellular marker. However, the PABL is not
critical if compounds studied are moderately lipophilic when per-
meability is less inﬂuenced by ABL (P0 < PABL). The Ppara is minimal
with use of tight monolayers.
4.5. IVIVC analysis
The P0 IVIVC analysis (Fig. 5) shows good predictive power of
the in vitro PBEC models for BBB permeability in vivo. Use of P0
was found to improve the correlation as compared to the conven-
tional in vitro Papp (Avdeef, 2011). In Avdeef (2011), the IVIVC P0
analysis for published data from porcine models gave a correlation
coefﬁcient, r2 of 0.58 (P < 0.001). In the present study, the r2
improved slightly from 0.58 to 0.61 for the pooled data, for a total
of 35 measurements (22 compounds).
The r2 obtained for the P0 IVIVC analysis in the present study is
lower than reported for an in vitro bovine BBB co-culture model
(Lundquist et al., 2002; Cecchelli et al., 2007). In those studies, lin-
ear correlation was tested for in vitro Papp vs. in vivo BUI data of ten
compounds; r2 of 0.86 was reported. The lower r2 in the present
study could result from uncertainties in P0 derivation, e.g. when
the measured data were too close to one of the DRW boundaries
(either ABL or paracellular limit), or when judgement has to be
made to determine pKaFLUX from assays for ionizable compounds
conducted at a single pH of 7.4, which is common for BBB research.
The low r2 may also reﬂect the use of pCEL-X predicted in situ P0values (acetylsalicylic acid and neramexane) and Caco-2 values
(dexamethasone and metoprolol) to ﬁll in gaps in the rodent
in situ brain perfusion database. The focus of the applications so
far has been to derive or predict the transcellular passive perme-
ability in vivo. Hence, in situ data for the training set were selected
from studies which used transporter knock-out animals, trans-
porter inhibitors or high concentration of compounds to saturate
transporters (Dagenais et al., 2009). Compounds reported to show
saturable transport were excluded. In the present study, the assays
for uptake compounds were not conducted in the presence of
inhibitors or saturating concentrations. Therefore, the permeability
values obtained were in some cases different from predictions. The
differences in transporter expression in different species (pig and
rodent) and also in different models used i.e. in vitro and in vivo
could also inﬂuence the r2. In the present study, the data collected
reﬂect evolution of the in vitro PBEC model from a low TEER cell
monolayer (below 200X cm2) to high TEER cell monolayer
(>1000X cm2) used for permeability assays and the new knowl-
edge of the restrictive effect of polyester ﬁlter membrane (Trans-
well-Clear) on permeability of lipophilic compounds. The cell
monolayer tightness and ﬁlter boundary deﬁne the DRW which
inﬂuences P0 derivation, hence could also inﬂuence r2. The larger
numbers of compounds in the IVIVC analysis in the present study
cover a wider chemical space compared to the correlation analysis
of ten compounds reported by Lundquist et al. (2002) which will
also inﬂuence r2. It should be noted that BUI measurement (over
15 s) is only suitable for rapidly-penetrating compounds,
whereas in situ brain perfusion (over up to 30 min) as used in the
IVIVC here can be used for compounds with a much greater range
of permeabilities.
In summary, the present study demonstrates ABL restriction to
permeability of the lipophilic compound propranolol. To avoid ﬁl-
ter restriction, it is crucial to select a suitable ﬁlter insert (polyester
or polycarbonate) as cell growth support to assay permeability.
Conducting permeability assay at multiple pH for ionizable com-
pounds provides an alternative method to correct for the ABL effect
without having to stir at a high rate during the assay; stirring will
tend to compromize the cell monolayer tight junction integrity,
reducing the resistance of the cell monolayer. The novel combina-
tion of a robust in vitro PBECmodel and pCEL-X software provides a
valuable tool to address the ABL effect as one limitation of an
in vitro permeability measurement, to better reﬂect and predict
permeation in vivo. Hence, the combination may prove a good
alternative to in vivo methods for BBB permeability screening. It
is clear that pCEL-X is able to handle historic and literature data,
but that using it in iterative mode during the design, conduct
and analysis of data is even more useful, and gives additional
insights into BBB permeation mechanisms.Conﬂicts of interest
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Education, Malaysia.Appendix A. Computational method – permeability model
The apparent permeability of an endothelial cell monolayer,
Papp, can be separated into four components – aqueous boundary
S.R. Yusof et al. / European Journal of Pharmaceutical Sciences 65 (2014) 98–111 109layer (PABL), ﬁlter (Pﬁlter), transcellular (PC), and paracellular (Ppara)
(Ho et al., 2000):
1
Papp
¼ 1
PABL
þ 1
Pfilter
þ 1
PC þ Ppara ðA:1Þ
PC represents the transcellular permeability contribution, associ-
ated with cell membranes (apical, basolateral and cytosol organelle)
and any contributions from carrier-mediated processes. For a mol-
ecule with a single ionizable group (ionization constant, pKa), PC is
deﬁned by a sigmoidal function:
PC ¼ P0
10ðpHpKaÞ þ 1
þ Pi
10ðpKapHÞ þ 1
þ    ðA:2Þ
where the ‘±’ is ‘+’ for acids and ‘’ for bases. The maximum possible
value of PC is the permeability of the neutral species, P0; the mini-
mum possible PC value is the permeability of the ionized species,
Pi. summarizes the relationship between these components of
permeability.
One objective of the data analysis was to determine P0 values
frommeasured Papp, since P0 values are expected to generate better
IVIVC compared to the Papp values (Avdeef, 2012). To do so,
selected marker molecules were used to estimate PABL, Pﬁlter, and
Ppara, with which Eqs. (A.1) and (A.2) can be solved for PC and P0.
A.1. Aqueous boundary layer permeability, PABL
PABL represents the total permeability of the two stagnant water
layers adjacent to the apical and basolateral monolayer surfaces
(cytosol water is a minor contribution, since the thickness of the
ABL substantially exceeds that of the cell). It can be estimated by
the expression
PABL ¼ D37aq=hABL ðA:3Þ
where hABL is the total thickness of the boundary layers, and Daq37 is
the empirically-determined aqueous diffusivity (cm2 s1) as a func-
tion of MW (Avdeef, 2012),
D37aq ¼ 0:991 104 MW0:453 ðA:4Þ
PABL may be obtained from the analysis of logPapp vs. pH. For a
highly permeable molecule, the maximum possible apparent per-
meability, Pappmax, is
log Pmaxapp ¼ log PABL  log
PABL
P0
þ 1
 
 log PABL ðA:5Þ
When P0 PABL (highly permeable molecules), then Pappmax  PABL,
indicating that water (not the membrane) limits transport. Propran-
olol at 200 RPM stirring was selected as an ABL marker in this study.
For PABL at stirring rates (m) other than 200 RPM (but greater
than zero), the ‘‘square-root’’ relationship was invoked (Avdeef,
2012):
PmABL ¼ P200ABL 
ﬃﬃﬃﬃﬃﬃﬃﬃ
m
200
r
ðA:6ÞA.2. Filter permeability, Pﬁlter
If the ﬁlter porosity ef and the ﬁlter thickness hf are known, the
ﬁlter permeability may be calculated according to
Pfilter ¼ ef Daq=hf ðA:7Þ
For polyester ﬁlter inserts, ef = 0.003–0.008 (‘clear ﬁlters’) and
for polycarbonate ﬁlter inserts, ef = 0.05–0.20 (‘translucent ﬁlters’),
depending on the commercial source. Ideally, these values need to
be veriﬁed experimentally, as was done for the PC ﬁlters used:
ef = 0.135 (Avdeef et al., 2005). It is not necessary to know theprecise PC ef value, because the PBEC model stirred at 6200 RPM
is limited more by the ABL resistance than the PC ﬁlter resistance
(PﬁlterPC PABL).
On the other hand, the ef value for PE was determined in the
present study, since PﬁlterPE  PABL. ‘‘Blank’’ PC and PE ﬁlter inserts
(treated with collagen but not coated with cell monolayers) were
used to estimate ef of the PE inserts. The experiment with blank
PC ﬁlters determined the ABL contribution due to the collagen
layer on the ﬁlters. The experiment was repeated with PE ﬁlter
inserts, all else being the same. In the second experiment, the PABL
determined from the PC experiment was included in the calcula-
tion to determine the Pﬁlter associated with the PE inserts, according
to Eqs. (A.1) and (A.6).
A.3. Paracellular permeability, PparaA.3.1. Transendothelial electrical resistance (TEER) as a measure of
Ppara
It is a common practice to use the TEER value to estimate the
tightness of paracellular junctions. The ease with which small sol-
vated ions, such as Na+ and Cl, can move through these channels
can be approximated by the TEER. Measured TEER values in the
intact blood–brain barrier are about 2000X cm2 (Butt et al.,
1990), but many in vitro brain endothelial cell (BEC) models show
TEER < 100X cm2 (Avdeef, 2011).
TEER values can be used to predict sucrose or mannitol perme-
ability (cm s1 units) in PBEC models using the empirical relation-
ship (Avdeef, 2012)
log Psucrose=mannitolapp ¼ 2:28 1:25 log TEER ðA:8Þ
(r2 = 0.97, s = 0.08 log units, n = 37). Sucrose and mannitol values
appear indistinguishable in PBEC measurements, suggesting that
sucrose is not appreciably metabolized in the cell assay. A linear
relationship is expected, since resistance (i.e., TEER) is inversely
related to conductance (i.e., permeability). The hydrodynamic (sol-
vated) radius of Na+ is often taken to be 4.0 Å, which is about the
average of sucrose (4.6 Å) and mannitol (3.6 Å).
A.3.2. Sucrose apparent permeability (Papp) as a measure of Ppara
Besides TEER measurements, the permeability of ‘marker’ mol-
ecules (e.g., urea, sucrose, rafﬁnose, and inulin) can indicate the
tightness and size-selectivity of the barrier. Sucrose was selected
as a paracellular marker in the study, to augment the TEER mea-
surements. The molecule is estimated to have a transendothelial
permeability logPC = 6.92 ± 0.49 (Avdeef, 2011), which sets the
lower limit for Ppara, PparaLOW, that could be measured using the para-
cellular marker. The upper limit for the marker, PparaHIGH, is set by the
aqueous diffusion resistance of the ABL and ﬁlter, which is equal to
logPABL + logPﬁlter  log(PABL + Pﬁlter), according to Eq. (A.1).
For any suitable paracellular marker molecule, Eq. (A.1) may be
rearranged to
Ppara ¼ Papp
1 Papp
PHIGHpara
  PLOWpara  Papp ðA:9Þ
Values of PparaHIGH are expected to be between 10–4.27 (PC ﬁlters,
200 RPM stirring) and 10–4.99 (PE ﬁlters, no stirring) cm s1. For
most of the molecules studied, Ppara = Papp of sucrose is a useful
approximation.
A.3.3. Parameterized paracellular equation
Based on in situ brain perfusion Ppara values of suitable paracel-
lular marker molecules, it is possible to parameterize the paracel-
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et al., 2000; Avdeef, 2010; Avdeef and Tam, 2010) as
Ppara ¼ ed  Daq  Fðr=RÞ  EðDuÞ þ
e
d
 
2
 Daq ðA:10Þ
The last term in the above equation describes the secondary
size- and charge-unspeciﬁed (‘‘free diffusion’’) pathway contribu-
tion, which is needed to describe the BBB permeation of large
hydrophilic molecules such as inulin (Avdeef, 2012). F(r/R) is the
Renkin hydrodynamic sieving function (Ho et al., 2000) for cylin-
drical water channels of radius R with diffusing molecules of a
hydrodynamic radius r. For large channels (r	 R), F(r/R)  1. The
estimated value of R at the BBB is 4.8 Å (Avdeef, 2012). The
E(Du) term in the above equation is a function of the potential
drop, Du, across the electric ﬁeld created by negatively-charged
residues lining the junctional pores. For very large channels
(r	 R) or for channels not lined with a high charge density,
E(Du)  1.
Avdeef (2011) quantitatively analyzed the paracellular proper-
ties of fourteen published BEC studies, with cell monolayers pre-
pared from several different animal species (primary and cell
lines). It was not possible to determine reliably the electrical
potential drop contribution for the in vitro BEC models. Also, most
cell models analyzed proved to be very leaky (especially human
cultures), with the exception of the porcine BEC mono-cultured
models of Franke et al. (1999, 2000), Lohmann et al. (2002), and
the bovine co-cultured models of Garberg et al. (2005) and
Lundquist et al. (2002). The ratio of Papp of sucrose to that of urea
was used as an indicator of size discrimination. In the meta-analy-
sis, most BEC models showed a ratio of 2–3. The highest was 8
(Lohmann porcine model). Tighter BBB junctions display a size-dis-
crimination ratio of about 40 (Avdeef, 2012).
Due to the uncertainty about charge density in the paracellular
channels and the relative leakiness, it was decided to approximate
Eq. (A.10) in the simpliﬁed ‘‘free diffusion’’ form
Ppara  ed
 
2
 Daq ðA:11ÞA.4. Transcellular permeability, PC
With the water diffusion terms estimated as described above, it
becomes possible to apply the pKaFLUX method (Avdeef et al., 2005)
to estimate logP0, from the analysis of logPapp vs. pH of a highly
permeable molecule. As long as the ABL contributes some resis-
tance to permeation, and thus pKaFLUX is deﬁned (i.e., P0 > PABL),
log P0 ¼ log PABL  ðpKFLUXa  pKaÞ ðA:12ÞA.5. Regression analysis
The computer program, pCEL-X (v4.01, in-ADME Research), cal-
culated the above permeability quantities from the provided
logPapp vs. pH data. A weighted nonlinear regression analysis based
on the logarithmic form of Eq. (A.1) was used (Avdeef, 2012) to
reﬁne the values of logP0, and in some cases, also logPABL and
logPpara or logPuptake. The weighted residuals function minimized is
Rw ¼
Xn
i
log Pobsapp;i  log Pcalcapp;i
riðlog PappÞ
 !2
ðA:13Þ
where n is the number of observed (i.e., measured) Papp values for a
particular molecule used in the model reﬁnement, and ri(logPapp) is
the estimated standard deviation of the logarithm of the ith Papp.
The effectiveness of the reﬁnement is characterized by the ‘good-
ness-of-ﬁt,’ GOF = [Rw/(n  nV)]1/2, where nV refers to the numberof varied parameters. The expected value of GOF is 1 if the model
is suitable for the data and the measured standard deviations accu-
rately reﬂect the precision of the data. (If n = 1, then nV cannot
exceed 1, and GOF is undeﬁned.)
A.6. Transformation of Kin into PC
in situ
The intrinsic BBB permeability values, P0in situ (ionization-cor-
rected apparent transcellular permeability values, PCin situ), were
used in the IVIVC. The transformation of the uptake clearance val-
ues (Kin) into transcellular permeability coefﬁcients (using the
Crone–Renkin equation) assumes that the ﬂux is unidirectional
and that a sink state is maintained; i.e., there is no appreciable
back-ﬂux. Any signiﬁcant contribution from the unstirred water
layer resistance on the abluminal side would challenge the
assumption.
Published in situ brain perfusion measurements (database in
Avdeef, 2012) generally used the protocol suggested by Takasato
et al. (1984), based on a simple, linear two-compartment model
(the vascular blood/perfusate and the brain parenchyma) in which
the perfusion time was limited to minimize the back-ﬂux of solutes
from brain parenchyma to the luminal perfusate. The perfusion
ﬂuid is commonly infused into the carotid artery at 10 mL/min
for rat (Allen and Smith, 2001) and 2.5 mL/min for mouse
(Dagenais et al., 2009). The perfusion times are generally selected
to be short (5–75 s; 60 s for sucrose) (Allen and Smith, 2001).
Times as long as 4 min may lead to some back-ﬂux for lipophilic
molecules (cf., the case of diazepam and propranolol: Mehta
et al., 2013).
Although entry to brain parenchyma for passively-distributing
lipophilic molecules is fast, the much larger distribution volume
beyond the capillary wall than contained within the microvessels
(98% cf. 2% of total) means that the concentration in the paren-
chyma adjacent to the endothelium will take time to build up suf-
ﬁciently to drive passive diffusion back into the perfusate
(Bradbury et al., 1975). Hence while it is true the brain parenchyma
is not a well-stirred compartment, the small distances involved for
diffusion (typically <25 lm to furthest neuron), and the close asso-
ciation of lipid membranes (pericytes, astrocyte endfeet) and other
binding sites (basement membrane/extracellular matrix) with the
basal side of the endothelium means that these provide ‘sink’ con-
ditions similar to the effect of including protein such as BSA in the
receiver compartment of in vitro studies such as the present one.
Hence these sink conditions dominate over any effect of a ‘in-series
diffusion barrier’ contributed by the abluminal UWL/ABL, which
can thus be ignored. Therefore, the BBB intrinsic permeability val-
ues used in the IVIVC are considered valid.References
Abbott, N.J., 2014. Anatomy and physiology of the blood–brain barriers. In:
Hammarlund-Udenaes, M., de Lange, E.C.M., Thorne, R.G. (Eds.), Drug Delivery
to the Brain. AAPS/Springer, New York, pp. 3–21 (Chapter 1).
Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., Begley, D.J., 2010. Structure
and function of the blood–brain barrier. Neurobiol. Dis. 37, 13–25.
Abbott, N.J., Dolman, D.E.M., Yusof, S.R., Reichel, A., 2014. In vitro models of CNS
barriers. In: Hammarlund-Udenaes, M., de Lange, E.C.M., Thorne, R.G. (Eds.),
Drug Delivery to the Brain. AAPS/Springer, New York, pp. 163–197 (Chapter 6).
Allen, D.D., Smith, Q.R., 2001. Characterization of the blood–brain barrier choline
transporter using the in situ rat brain perfusion technique. J. Neurochem. 76,
1032–1041.
Avdeef, A., 2010. Leakiness and size exclusion of paracellular channels in cultured
epithelial cell monolayers – interlaboratory comparison. Pharm. Res. 27, 480–
489.
Avdeef, A., 2011. How well can in vitro brain microcapillary endothelial cell models
predict rodent in vivo blood–brain barrier permeability? Eur. J. Pharm. Sci. 14,
109–124.
Avdeef, A., 2012. Absorption and Drug Development, second ed. Wiley-Interscience,
Hoboken, NJ.
S.R. Yusof et al. / European Journal of Pharmaceutical Sciences 65 (2014) 98–111 111Avdeef, A., Tam, K.Y., 2010. Howwell can the Caco-2/MDCK models predict effective
human jejunal permeability? J. Med. Chem. 53, 3566–3584.
Avdeef, A., Nielsen, P.E., Tsinman, O., 2004. PAMPA – a drug absorption in vitro
model 11. Matching the in vivo unstirred water layer thickness by individual-
well stirring in microtitre plates. Eur. J. Pharm. Sci. 22, 365–374.
Avdeef, A., Artursson, P., Neuhoff, S., Lazorova, L., Gråsjö, J., Tavelin, S., 2005. Caco-2
permeability of weakly basic drugs predicted with the double-sink PAMPA
pKa(ﬂux) method. Eur. J. Pharm. Sci. 24, 333–349.
Balakrishnan, A., Hussainzada, N., Gonzalez, P., Bermejo, M., Swaan, P.W., Polli, J.E.,
2007. Bias in estimation of transporter kinetic parameters from overexpression
systems: interplay of transporter expression level and substrate afﬁnity. J.
Pharmacol. Exp. Ther. 320, 133–144.
Barry, P.H., Diamond, J.M., 1984. Effects of unstirred layers on membrane
phenomena. Physiol. Rev. 64, 763–872.
Bernas, M.J., Cardoso, F.L., Daley, S.K., Weinand, M.E., Campos, A.R., Ferreira, A.J.,
Hoying, J.B., Witte, M.H., Brites, D., Persidsky, Y., Ramirez, S.H., Brito, M.A., 2010.
Establishment of primary cultures of human brain microvascular endothelial
cells to provide an in vitro cellular model of the blood–brain barrier. Nat. Protoc.
5, 1265–1272.
Bradbury, M.W.B., Patlak, C.S., Oldendorf, W.H., 1975. Analysis of brain uptake
and loss of radiotracers after intracarotid injection. Am. J. Physiol. 229, 1110–
1115.
Butt, A.M., Jones, H.C., Abbott, N.J., 1990. Electrical resistance across the blood–brain
barrier in anaesthetized rats: a developmental study. J. Physiol. 429, 47–62.
Carl, S.M., Lindley, D.J., Couraud, P.O., Weksler, B.B., Romero, I., Mowery, S.A., Knipp,
G.T., 2010. ABC and SLC transporter expression and proton oligopeptide
transporter (POT) mediated permeation across the human CMEC/D3 blood–
brain barrier cell line. Mol. Pharm. 7, 1057–1068.
Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.P.,
Fenart, L., 2007. Modelling of the blood–brain barrier in drug discovery and
development. Nat. Rev. Drug Discov. 6, 650–661.
Cohen-Kashi Malina, K., Cooper, I., Teichberg, V.I., 2009. Closing the gap between the
in-vivo and in-vitro blood–brain barrier tightness. Brain Res. 1284, 12–21.
Culot, M., Lundquist, S., Vanuxeem, D., Nion, S., Landry, C., Delplace, Y., Dehouck,
M.P., Berezowski, V., Fenart, L., Cecchelli, R., 2008. An in vitro blood–brain
barrier model for high throughput (HTS) toxicological screening. Toxicol. In
Vitro 22, 799–811.
Cussler, E.L., 1997. Diffusion – Mass Transfer in Fluid Systems, second ed.
Cambridge Univ. Press, Cambridge, UK, pp. 111–121.
Dagenais, C., Avdeef, A., Tsinman, O., Dudley, A., Beliveau, R., 2009. P-glycoprotein
deﬁcient mouse in situ blood–brain barrier permeability and its prediction
using an in combo PAMPA model. Eur. J. Pharm. Sci. 38, 121–137.
Dickens, D., Yusof, S.R., Abbott, N.J., Weksler, B., Romero, I.A., Couraud, P.O., Alﬁrevic,
A., Pirmohamed, M., Owen, A., 2013. A multi-system approach assessing the
interaction of anticonvulsants with P-gp. PLoS ONE 8, e64854.
Förster, C., Silwedel, C., Golenhofen, N., Burek, M., Kietz, S., Mankertz, J.,
Drenckhahn, D., 2005. Occludin as direct target for glucocorticoid-induced
improvement of blood–brain barrier properties in a murine in vitro system. J.
Physiol. 565, 475–486.
Franke, H., Galla, H.J., Beuckmann, C.T., 1999. An improved low-permeability
in vitro-model of the blood–brain barrier: transport studies on retinoids,
sucrose, haloperidol, caffeine and mannitol. Brain Res. 818, 65–71.
Franke, H., Galla, H., Beuckmann, C.T., 2000. Primary cultures of brain microvessel
endothelial cells: a valid and ﬂexible model to study drug transport through the
blood–brain barrier in vitro. Brain Res. Brain Res. Protoc. 5, 248–256.
Gaillard, P.J., de Boer, A.G., 2000. Relationship between permeability status of the
blood–brain barrier and in vitro permeability coefﬁcient of a drug. Eur. J. Pharm.
Sci. 12, 95–102.
Garberg, P., Ball, M., Borg, N., Cecchelli, R., Fenart, L., Hurst, R.D., Lindmark, T.,
Mabondzo, A., Nilsson, J.E., Raub, T.J., Stanimirovic, D., Terasaki, T., Oberg, J.O.,
Osterberg, T., 2005. In vitro models for the blood–brain barrier. Toxicol. In Vitro
19, 299–334.
Gutknecht, J., Tosteson, D.C., 1973. Diffusion of weak acids across lipid membranes:
effects of chemical reactions in the unstirred layers. Science 182, 1258–1261.
Hatherell, K., Couraud, P.O., Romero, I.A., Weksler, B., Pilkington, G.J., 2011.
Development of a three-dimensional, all-human in vitro model of the blood–
brain barrier using mono-, co-, and tri-cultivation Transwell models. J. Neurosci.
Methods 199, 223–229.
Hidalgo, I.J., Hillgren, K.M., Grass, G.M., Borchardt, R.T., 1991. Characterization of the
unstirred water layer in Caco-2 cell monolayers using a novel diffusion
apparatus. Pharm. Res. 8, 222–227.
Ho, N.F.H., Raub, T.J., Burton, P.S., Barsuhn, C.L., Adson, A., Audus, K.L., Borchardt, R.,
2000. Quantitative approaches to delineate passive transport mechanisms in
cell culture monolayers. In: Amidon, G.L., Lee, P.I., Topp, E.M. (Eds.), Transport
Processes in Pharmaceutical Systems. Marcel Dekker, New York, NY, pp. 219–
316.
Hoheisel, D., Nitz, T., Franke, H., Wegener, J., Hakvoort, A., Tilling, T., Galla, H.J., 1998.
Hydrocortisone reinforces the blood–brain properties in a serum free cell
culture system. Biochem. Biophys. Res. Commun. 247, 312–315.
Hudetz, A.G., 1997. Blood ﬂow in the cerebral capillary network: a review
emphasizing observations with intravital microscopy. Microcirculation 4,
233–252.
Karlsson, J.P., Artursson, P., 1991. A method for the determination of cellular
permeability coefﬁcients and aqueous boundary layer thickness in monolayers
of intestinal epithelial (Caco-2) cells grown in permeable ﬁlter chambers. Int. J.
Pharm. 7, 55–64.Katneni, K., Charman, S.A., Porter, C.J., 2008. An evaluation of the relative roles of the
unstirred water layer and receptor sink in limiting the in-vitro intestinal
permeability of drug compounds of varying lipophilicity. J. Pharm. Pharmacol.
60, 1311–1319.
Korjamo, T., Heikkinen, A.T., Waltari, P., Mönkkönen, J., 2008. The asymmetry of the
unstirred water layer in permeability experiments. Pharm. Res. 25, 1714–1722.
Korjamo, T., Heikkinen, A.T., Mönkkönen, J., 2009. Analysis of unstirred water layer
in in vitro permeability experiments. J. Pharm. Sci. 98, 4469–4479.
Lippmann, E.S., Al-Ahmad, A., Palecek, S.P., Shusta, E.V., 2013. Modeling the blood–
brain barrier using stem cell sources. Fluids Barriers CNS 10, 2.
Loftsson, T., Brewster, M.E., 2008. Physicochemical properties of water and its effect
on drug delivery. A commentary. Int. J. Pharm. 16, 248–254.
Lohmann, C., Hüwel, S., Galla, H.J., 2002. Predicting blood–brain barrier
permeability of drugs: evaluation of different in vitro assays. J. Drug Target.
10, 263–276.
Lundquist, S., Renftel, M., Brillault, J., Fenart, L., Cecchelli, R., Dehouck, M.P., 2002.
Prediction of drug transport through the blood–brain barrier in vivo: a
comparison between two in vitro cell models. Pharm. Res. 19, 976–981.
Mehta, D.C., Short, J.L., Nicolazzo, J.A., 2013. Altered brain uptake of therapeutics in
a triple transgenic mouse model of Alzheimer’s disease. Pharm. Res. 30, 2868–
2879.
Nakagawa, S., Deli, M.A., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, A.,
Tanaka, K., Niwa, M., 2009. A new blood–brain barrier model using primary rat
brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 54, 253–263.
Naruhashi, K., Tamai, I., Li, Q., Sai, Y., Tsuji, A., 2003. Experimental demonstration of
the unstirred water layer effect on drug transport in Caco-2 cells. J. Pharm. Sci.
92, 1502–1508.
Ng, K.Y., Grass, G., Lane, H., Borchardt, R.T., 1993. Characterization of the unstirred
water layer in cultured brain microvessel endothelial cells. In Vitro Cell. Dev.
Biol. Anim. 29A, 627–629.
Nielsen, P.E., Avdeef, A., 2004. PAMPA – a drug absorption in vitro model 8.
Apparent ﬁlter porosity and the unstirred water layer. Eur. J. Pharm. Sci. 22, 33–
41.
Patabendige, A., Skinner, R.A., Abbott, N.J., 2013a. Establishment of a simpliﬁed
in vitro porcine blood–brain barrier model with high transendothelial electrical
resistance. Brain Res. 1521, 1–15.
Patabendige, A., Skinner, R.A., Morgan, L., Abbott, N.J., 2013b. A detailed method for
preparation of a functional and ﬂexible blood–brain barrier model using porcine
brain endothelial cells. Brain Res. 1521, 16–30.
Prins, L.H., du Preez, J.L., van Dyk, S., Malan, S.F., 2009. Polycyclic cage structures as
carrier molecules for neuroprotective non-steroidal anti-inﬂammatory drugs.
Eur. J. Med. Chem. 44, 2577–2582.
Rubin, L.L., Hall, D.E., Porter, S., Barbu, K., Cannon, C., Horner, H.C., Janatpour, M.,
Liaw, C.W., Manning, K., Morales, J., Tanner, L.I., Tomaselli, K.J., Bard, F., 1991. A
cell culture model of the blood–brain barrier. J. Cell Biol. 115, 1725–1735.
Ruell, J.A., Tsinman, K.L., Avdeef, A., 2003. PAMPA – a drug absorption in vitro
model. 5. Unstirred water layer in iso-pH mapping assays and pKa(ﬂux) –
optimized design (pOD-PAMPA). Eur. J. Pharm. Sci. 20, 393–402.
Sano, Y., Shimizu, F., Abe, M., Maeda, T., Kashiwamura, Y., Ohtsuki, S., Terasaki, T.,
Obinata, M., Kajiwara, K., Fujii, M., Suzuki, M., Kanda, T., 2010. Establishment of
a new conditionally immortalized human brain microvascular endothelial cell
line retaining an in vivo blood–brain barrier function. J. Cell. Physiol. 225, 519–
528.
Skinner, R.A., Gibson, R.M., Rothwell, N.J., Pinteaux, E., Penny, J.I., 2009. Transport of
interleukin-1 across cerebromicrovascular endothelial cells. Br. J. Pharmacol.
156, 1115–1123.
Strom, S.C., Michalopoulos, G., 1982. Collagen as a substrate for cell growth and
differentiation. Methods Enzymol. 82, 544–555.
Suzuki, T., Ohmuro, A., Miyata, M., Furuishi, T., Hidaka, S., Kugawa, F., Fukami, T.,
Tomono, K., 2010. Involvement of an inﬂux transporter in the blood–brain
barrier transport of naloxone. Biopharm. Drug Dispos. 31, 243–252.
Takasato, Y., Rapoport, S.I., Smith, Q.R., 1984. An in situ brain perfusion technique to
study cerebrovascular transport in the rat. Am. J. Physiol. 247, H484–H493.
Vandenhaute, E., Sevin, E., Hallier-Vanuxeem, D., Dehouck, M.P., Cecchelli, R., 2012.
Case study: adapting in vitro blood–brain barrier models for use in early-stage
drug discovery. Drug Discov. Today 17, 285–290.
Velicky´, M., Bradley, D.F., Tam, K.Y., Dryfe, R.A., 2010. In situ artiﬁcial membrane
permeation assay under hydrodynamic control: permeability-pH proﬁles of
warfarin and verapamil. Pharm. Res. 27, 1644–1658.
Villringer, A., Them, A., Lindauer, U., Einhäupl, K., Dirnagl, U., 1994. Capillary
perfusion of the rat brain cortex. An in vivo confocal microscopy study. Circ. Res.
75, 55–62.
Wilson, F.A., Dietschy, J.M., 1974. The intestinal unstirred layer: its surface area and
effect on active transport kinetics. Biochim. Biophys. Acta 363, 112–126.
Xue, Q., Liu, Y., Qi, H., Ma, Q., Xu, L., Chen, W., Chen, G., Xu, X., 2013. A novel brain
neurovascular unit model with neurons, astrocytes and microvascular
endothelial cells of rat. Int. J. Biol. Sci. 9, 174–189.
Youdim, K.A., Avdeef, A., Abbott, N.J., 2003. In vitro trans-monolayer permeability
calculations: often forgotten assumptions. Drug Discov. Today 8, 997–1003.
Yu, H., Sinko, P.J., 1997. Inﬂuence of the microporous substratum and
hydrodynamics on resistances to drug transport in cell culture systems:
calculation of intrinsic transport parameters. J. Pharm. Sci. 86, 1448–1457.
Zhang, Y., Li, C.S., Ye, Y., Johnson, K., Poe, J., Johnson, S., Bobrowski, W., Garrido, R.,
Madhu, C., 2006. Porcine brain microvessel endothelial cells as an in vitro model
to predict in vivo blood–brain barrier permeability. Drug Metab. Dispos. 34,
1935–1943.
